Region — US. Neutral scientific reference — not offered for sale here.
Cart · 0
Set region
Vallydia
ExploreShopToolsJournalTrust
Explore  /  Epithalamin
Research reference — not for sale

Epithalamin

F
lead outcome
Independent replication of any finding
grades vary by outcome ↓
Peptide
also called — epithalamine · pineal peptide preparation · bovine pineal extract · Эпиталамин · INCI: none
pineal peptide preparationmelatonin rhythm (proposed)geroprotection (claimed)

Status: reference entry — not for sale. No dosing, reconstitution, or administration is published (intentional). Neutral scientific reference only. Epithalamin is an undefined bovine tissue extract; material sold under this name has no established relationship to the preparations used in the published studies.

In brief

Epithalamin is a polypeptide extract of bovine pineal gland, developed from the 1970s by Vladimir Khavinson and colleagues at the St Petersburg Institute of Bioregulation and Gerontology as the founding compound of the "peptide bioregulator" framework. The reported findings are dramatic: 20-40% lifespan extension across rodents and Drosophila, restored melatonin rhythms in elderly humans, and — the headline claim — a 2-to-4-fold lower mortality over 6-8 years in 266 elderly subjects given epithalamin together with thymalin. Three things have to be said about that record. Every study, preclinical and clinical, comes from the originating group, with no independent confirmation, and roughly half the ~110 papers are in Russian without English translation. The mortality study was neither randomised nor blinded, and its result applies to a two-compound combination, not to epithalamin alone. And epithalamin itself is an undefined mixture of bovine-derived polypeptides whose composition likely varies between preparations — so mechanistic claims cannot be attributed to any specific component, and nothing sold today can be assumed identical to what was studied. Its defined synthetic successor, epitalon (AEDG), has a separate entry; the two are not interchangeable, and where compared, they have diverged.

Legal standing, by region
European Union
Not approved

No marketing authorisation as a medicine in the EU. Not an authorised novel food or cosmetic ingredient. Bovine tissue-derived preparations face additional regulatory scrutiny in the EU. Material sold online is neither authorised nor quality-assured.

United Kingdom
Not approved

No marketing authorisation.

United States · your region
Not FDA-approved; categorically ineligible for compounding

Not FDA-approved for any indication. As a **bovine pineal tissue extract**, epithalamin is categorically ineligible as a bulk drug substance for 503A compounding — it is not a component of an FDA-approved drug, is not the subject of a USP/NF monograph, and is not on the FDA bulk substances list. This is a stronger exclusion than applies to defined synthetic peptides.

International
Registered in Russia; not approved in Western jurisdictions

Developed and used within the Russian medical system by the St Petersburg Institute of Bioregulation and Gerontology. Approval or registration in that context does not correspond to EMA or FDA standards of evidence, and does not transfer.

Evidence, by outcome
How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Independent replication of any finding
This is the defining fact of the entry, and it applies to everything below. A large body of internally consistent work from a single group, half of it inaccessible to outside review, is a different class of evidence from replicated science — regardless of how many papers it contains.
The Alzheimer's Drug Discovery Foundation's Cognitive Vitality review of epithalamin and epithalon states directly that **every preclinical and clinical study has been conducted by Khavinson's group in Russia, with no independent confirmation of their results**. It further notes that at least half of the roughly 110 published articles on epithalamin and epithalon are in Russian without English translations, and so could not be assessed. · No finding attributed to epithalamin has been independently reproduced outside the originating programme.
F
Melatonin rhythm in elderly humans
Small, uncontrolled human studies from within the originating programme. And a direct inconsistency sits inside the same literature: the synthetic tetrapeptide epitalon **failed** to stimulate melatonin production in rats (Djeridane et al., 2003) while the extract reportedly did — a discrepancy the reviewing literature flags as unexplained, and one that undercuts the assumption that the extract and its isolated peptide are interchangeable.
Korkushko et al. (2004) reported that epithalamin stimulated melatonin production in elderly adults with pineal dysfunction; supporting animal work in old rats (Anisimov et al., 1992). · Reported normalisation of melatonin rhythm in small studies.
D
Mortality reduction in elderly humans (the headline claim)
The methodological limits are severe and need stating plainly. The study was **not randomised and not blinded**. The mortality result applies to the **thymalin + epithalamin combination**, not to epithalamin alone. Controls received standard care rather than placebo, in an unblinded design over years, in a population where selection and attention effects are substantial. And it has never been replicated by anyone else. A 2-to-4-fold mortality reduction from a peptide extract would be one of the most important findings in geriatric medicine if it were robust; that it has attracted no independent replication attempt in over two decades is itself informative.
Khavinson's 2003 report in Neuroendocrinology Letters described a 6-to-8-year follow-up of 266 elderly subjects receiving thymalin, epithalamin, or both, versus standard geriatric care. Combined treatment was reported to be associated with mortality rates 2- to 4-fold lower than controls, alongside reported improvements in immune, endocrine and cardiovascular markers. · A large reported mortality difference — the most striking claim in the entire bioregulator literature.
D
Lifespan extension in animals
Twenty-five-plus years of work, all from one programme, much of it published in venues and languages that limited outside scrutiny. Rodent lifespan claims of 20-40% are very large — larger than caloric restriction in many strains — and such magnitudes are exactly what independent replication exists to check. None has been done. Note also that the more rigorous, purified successor compound (epitalon) produced a far more modest 12.3% extension in the same programme's own later work.
Long-running work from the same programme reports increased mean and maximum lifespan and slower ageing in rats, mice and Drosophila; increased pineal synthesis of serotonin, N-acetylserotonin and melatonin; effects on luteinising hormone and prolactin; delayed age-related cessation of oestrous function. A 2010 Biogerontology review by Anisimov and colleagues summarised 20-40% lifespan extension across the bioregulator class. · Consistent reported geroprotective effects across several species.
C
Composition and batch consistency
This is a fundamental problem, not a technicality. An undefined animal-tissue extract of variable composition cannot support precise mechanistic claims, cannot be reliably reproduced between batches or manufacturers, and cannot be assumed identical to whatever was used in the original studies. Any product sold today as "epithalamin" has no established relationship to the material in Khavinson's papers.
Epithalamin is a **mixture of polypeptides extracted from bovine pineal glands**, not a defined single molecule. The Cognitive Vitality review notes that because it is a mixture, it is impossible to determine which effects are attributable to which component, and that contents likely vary between preparations. · Not characterised as a defined substance.
F
Relationship to epitalon (AEDG)
The two are routinely discussed as interchangeable and are not. The **human clinical program used epithalamin (the extract)**; most **mechanistic work uses epitalon (the peptide)**; and where they have been compared, results have diverged (the melatonin discrepancy above). Evidence for one should not be cited for the other. See the separate epitalon entry.
Epitalon is the synthetic tetrapeptide Ala-Glu-Asp-Gly, developed as the isolated active principle of epithalamin. Its genuine presence in the bovine pineal complex was formally confirmed by mass spectrometry only in 2017 (Khavinson, Kopylov, Vaskovsky, Ryzhak & Lin'kova, Bulletin of Experimental Biology and Medicine). · Epitalon is the defined synthetic successor; most mechanistic research has moved to it, while the human clinical claims rest on the extract.
—
Human safety
Epithalamin is a **bovine tissue extract**. Animal-derived tissue preparations carry categorically different considerations from synthetic peptides — including immunogenicity and, historically, transmissible spongiform encephalopathy concerns that shaped regulation of bovine-derived materials generally. Safety reported by the manufacturer-adjacent research programme, in an undefined preparation of variable composition, is not a safety dataset.
No adequate independent safety characterisation. Long-term administration in the originating programme's studies was reported without notable adverse events. · Not established.
—
Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Epithalamin changes - nothing else.

One ingredient, one purpose. No marketing, no sharing. Unsubscribe anytime. See our privacy policy.

Identity

Epithalamin is not a defined molecule. It is a peptide preparation extracted from the pineal glands of cattle — a mixture of polypeptides whose exact composition is not fully characterised and, by the reviewing literature's assessment, likely varies between preparations. This matters more than it might appear: most entries in this register describe a single substance with a structure, a molecular weight and a CAS number. Epithalamin has none of these, and cannot.

It is the founding compound of what Khavinson's group termed peptide bioregulators — the framework proposing that short peptides from specific organs act as tissue-specific regulatory signals, that their decline drives ageing, and that supplying them exogenously can slow it. Its defined synthetic successor is epitalon (also spelled epithalon), the tetrapeptide Ala-Glu-Asp-Gly (AEDG), isolated as the proposed active principle. The two are constantly conflated and should not be.

Development & history

  • 1970s: Vladimir Khavinson and V. G. Morozov, working in what became the St Petersburg Institute of Bioregulation and Gerontology, develop epithalamin from bovine pineal tissue and begin the bioregulator research programme.
  • 1980s–1990s: Extensive animal work reported by the group — increased mean and maximum lifespan in rats, mice and Drosophila; increased pineal serotonin, N-acetylserotonin and melatonin synthesis; effects on luteinising hormone, prolactin and oestrous function in ageing rats. Summarised in Annals of the New York Academy of Sciences (1992, 1994).
  • 2002: Khavinson publishes the foundational monograph setting out the peptide bioregulation framework (Neuroendocrinology Letters).
  • 2003: The programme's central human claim appears — a 6-to-8-year follow-up of 266 elderly subjects given thymalin, epithalamin or both versus standard geriatric care, reporting 2-to-4-fold lower mortality in the combination group (Neuroendocrinology Letters).
  • 2004: Korkushko et al. report epithalamin stimulating melatonin production in elderly adults with pineal dysfunction.
  • 2003, contrarily: Djeridane et al. report that the synthetic epitalon failed to stimulate melatonin production in rats — a divergence between extract and isolated peptide that the literature does not resolve.
  • 2010: Anisimov and Khavinson review the class in Biogerontology, summarising 20-40% lifespan extension across bioregulator preparations.
  • 2017: Mass spectrometry formally confirms that AEDG is genuinely present in the bovine pineal complex, rather than being purely a rational-design analogue (Bulletin of Experimental Biology and Medicine).
  • Throughout and since: no independent group has attempted replication of the human findings.

Mechanism (as proposed)

The proposed mechanism is restoration of pineal signalling. Epithalamin is held to increase pineal synthesis and nocturnal secretion of melatonin, normalising circadian rhythm in ageing organisms where pineal function has declined, with downstream effects on the hypothalamic-pituitary axis — reduced luteinising hormone and prolactin, altered feedback sensitivity to oestrogens, preserved reproductive cycling. Antioxidant effects on free-radical oxidation are also reported. Within the bioregulator framework more broadly, tissue-specific peptides are proposed to act at the level of gene expression regulation.

The honest constraint on all of this: because epithalamin is a mixture, no reported effect can be assigned to a specific molecule. The mechanism as stated describes what a heterogeneous, incompletely characterised extract is proposed to do.

Reading the evidence honestly

Epithalamin has the largest body of reported longevity evidence of anything in this register, and the weakest evidential structure. Four points.

No independent confirmation exists. This is not a matter of interpretation — the ADDF's Cognitive Vitality reviewers state it explicitly, and it holds across preclinical and clinical work alike. Two and a half decades of consistent results from one institute, with no outside group having reproduced any of it, is a specific and serious limitation. Consistency within a programme measures the programme's internal reliability, not the finding's truth.

Roughly half the literature cannot be independently assessed. Around 110 papers exist on epithalamin and epitalon; approximately half are in Russian with no English translation, and were excluded from the independent review for that reason. A body of evidence that outside reviewers cannot read is not a body of evidence outside reviewers can endorse.

The mortality claim is the weakest kind of strong claim. A 2-to-4-fold mortality reduction in elderly people would be transformative if real. But the study was unblinded, unrandomised, controls received standard care rather than placebo, the result belongs to a two-drug combination, and no one has tried to repeat it in over twenty years. Extraordinary claims from non-randomised designs are precisely where medicine has most often been misled, and the absence of any replication attempt — by anyone, anywhere — is itself a signal.

The substance is undefined. An uncharacterised bovine tissue extract of probably-variable composition cannot support precise mechanistic claims, and nothing sold under the name today has a demonstrated relationship to what was studied. Its regulatory treatment reflects this: in the US, bovine pineal extract is categorically ineligible for pharmacy compounding, a stricter exclusion than applies to defined synthetic peptides.

None of this means the underlying hypothesis is wrong. Pineal decline with age is real, melatonin rhythm disruption in the elderly is real, and the bioregulator idea is not absurd. But the grade here reflects evidence quality, not plausibility — and by that measure, epithalamin remains, after fifty years, an unreplicated single-programme claim built on an undefined preparation.

Sources — 9 cited
01Khavinson VKh, Morozov VG, Anisimov VN. Experimental studies of the pineal gland preparation epithalamin. (monograph chapter summarising 25 years of the programme's work)
02Anisimov VN, Bondarenko LA, Khavinson VKh. Effect of pineal peptide preparation (epithalamin) on life span and pineal and serum melatonin level in old rats. Ann N Y Acad Sci. 1992;673:53-57.
03Anisimov VN, Khavinson VKh, Morozov VG. Twenty years of study on effects of pineal peptide preparation: epithalamin in experimental gerontology and oncology. Ann N Y Acad Sci. 1994;719:483-493.
04Khavinson VKh. Peptides and ageing. Neuroendocrinol Lett. 2002 (the foundational monograph setting out the bioregulator framework).
05Khavinson VKh, et al. Geroprotective effects of thymalin and epithalamin: 6-8 year follow-up of 266 elderly subjects. Neuroendocrinol Lett. 2003.
06Korkushko OV, et al. (2004) — epithalamin and melatonin production in elderly adults with pineal dysfunction.
07Djeridane Y, et al. (2003) — epitalon failed to stimulate melatonin production in rats (the discrepancy with the extract).
08Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010.
09Alzheimer's Drug Discovery Foundation, Cognitive Vitality: Epithalamin and Epithalon — research review noting absence of independent confirmation and untranslated literature.
Updated 2026-07-22 (the open question is unchanged since the 1990s — whether any independent group will attempt replication; re-check for any non-Khavinson study)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
Epitalon (Epithalon)C
Peptide
ThymalinC
Peptide
OxytocinA
Peptide
Explore by goal
Longevity & cellular →Sleep & circadian →Immune & thymic →
Vallydia

A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.

Region — United States
ExploreRegisterThe Register — full indexCategoriesTrust & COAHow we gradeOpen data
ShopCosmetic peptidesJournalQuizzes
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.

Epithalamin — evidence, uses & regulatory status · Vallydia